Pharmacy News

Generic Drugs

Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days

Articles(s): 1 - 7 of 7 Go To Page:

9/3/10 - SALIX PHARMACEUTICALS LTD FILES (8-K) Disclosing Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, we filed a lawsuit against Novel Laboratories, Inc. because Novel is seeking FDA approval to market a generic version of our MoviPrep product. Norgine, B.V. and Norgine Europe, B.V., which we refer to collectively as Norgine, own U.S. Patent No. 7,169,381.

9/2/10 - Lilly gets win with ruling on Evista [The Indianapolis Star]

Sept. 02After two stinging legal setbacks this summer over its drug patents, Eli Lilly and Co. has found the third time is a charm. A federal appeals court on Wednesday upheld a pair of key patents on the Indianapolis company's osteoporosis drug Evista, meaning that generic drug maker Teva Pharmaceuticals will not be able to sell a copy of the bl

9/2/10 - Teva loses Evista appeal [Globes, Tel Aviv, Israel]

Sept. 02Teva Pharmaceutical Industries Ltd. has lost its appeal to market a generic version of Eli Lilly and Company's osteoporosis drug Evista. US sales of Evista amount to $682 million a year. In 2008, Teva obtained provisional US Food and Drug Administration approval to market generic Evista.

9/2/10 - Trends in Generics Industry Ownership: Evaluating Changing Industry Paradigms and Emerging Players

Dublin - Research and Markets. has announced the addition of the "Trends in Generics Industry Ownership: Evaluating Changing Industry Paradigms and Emerging Players" report to their offering.

9/1/10 - [AIDS]-FDA Notifications: Generic Zidovudine injection approved

Generic Zidovudine injection approved.

9/1/10 - Sun Pharma announces FDA approval for generic Strattera capsules

Sun Pharmaceutical Industries, a speciality pharmaceutical company, has announced that the FDA has granted its subsidiary an approval for its abbreviated new drug application to market a generic version of Strattera, atomoxetine hydrochloride capsules.

8/31/10 - CVGW, WPI, NKE, SNIC, ACL, ZOLL Are Seasonally Ripe To Go Higher In The Next 4 Weeks

BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Calavo Growers, Watson Pharmaceuticals, Nike, Sonic Solutions, Alcon and Zoll Medical and each have a high seasonal probability to go higher in the next 5 weeks. http://www.squeezetrigger.com/services/strat/mh.php. The following stocks are expected to go higher: Symbol Company Exp

Articles(s): 1 - 7 of 7 Go To Page: